Toronto, Ontario, Canada -- October
20, 2021 -- InvestorsHub NewsWire -- GreenBank Capital
Inc. (CSE:
GBC and OTCMKTS:
GRNBF and FRA: 2TL) ("GreenBank" or "the Company") is very
pleased to announce that its portfolio company CodiKoat has
successfully completed its previously- disclosed pilot tests of its
"GoVirol" anti-viral coating product. The tests were conducted at
the world-famous Royal Opera House in the heart of London by
Codikoat's own scientists over the course of a three month period
between the middle of May 2021 and the middle of August
2021.
Highlights
- CodiKoat engages in three month
trial at the Royal Opera House for testing the efficacy of its
GoVirol antiviral coating in a high-traffic real-world
environment.
- After 3 months, the GoVirol coated
samples displayed exceptional antiviral results, killing 99% of
viruses within seconds of contact - including coronavirus
particles.
- Efficacy remained constant
throughout the trial – the GoVirol product was shown to be as
effective on the last day of the trial as it was on the first,
supporting CodiKoat's own lifetime protection laboratory
tests
- Another important step closer to
commercialization
- GoVirol, when widely produced and
used, has the potential to radically reduce hospital-acquired
healthcare-associated bacterial and viral infections
("HAI's"). HAI's have been estimated to cost the US economy up to
as much as $45bn per year and affect approximately 2 million
patients annually in the USA alone. (source: https://www.tandfonline.com/doi/full/10.1586/erp.09.53)
Trial Results
As part of the trial, CodiKoat
applied its antiviral coating "GoVirol" to a number of frequently
touched surfaces within London's Royal Opera House for a continuous
period during the months of May 2021 through August
2021.
The samples were monitored by
CodiKoat scientists throughout the pilot testing period, who
measured GoVirol's ability to remove viruses and harmful bacteria
from the surfaces, as well as the durability of the
application.
After 3 months, the GoVirol coated
samples maintained exceptional antiviral results, killing 99% of
viruses within seconds of contact - including coronavirus
particles.
The GoVirol samples were put to the
test by venue-goers, having been estimated to have been touched on
average over 250 times per day. This amounts to an estimated 22,000
times in total per sample, over the course of the 3 month testing
period.
Importantly, despite undergoing
rigorous cleaning regimes on a regular basis and the high frequency
of contact, the GoVirol samples were shown to be just as effective
on the final day of the trial as they had been on the
first.
As the world continues to do battle
against the COVID-19-causing coronavirus pandemic, GreenBank
believes that CodiKoat's coronavirus-killing antiviral solutions
can serve as highly valuable tools for reducing viral
transmission.
The outstanding performance and
durability shown in the Royal Opera House trials is consistent with
CodiKoat's own laboratory-based testing and moves GoVirol another
step closer to commercialization.
The GoVirol surface coating has
seemingly limitless applications and can be applied to virtually
any surface or material. The trial demonstrates that GoVirol can be
deployed to help minimize fomit (touch) viral, bacterial and fungal
transmission in major public spaces including entertainment venues,
public transport, healthcare, as well as touch screen pads,
smartphones and more.
GoVirol has already achieved ISO
21702:2019 certification, confirming its efficacy in the
eradication of human coronavirus NL63 in a regulated environment.
The International Standards Organisation (ISO) is a global network
of the world's leading standardisers. Through its members
(the national standards bodies in 165 different countries) the ISO
brings together experts from all over the world to develop
International Standards. ISO 21702:2019 is a standard issued by the
ISO for measuring antiviral activity on plastics and other
non-porous surfaces of antiviral-treated products against specified
viruses.
Whilst the ISO test was not
conducted specifically on SARS-CoV-2 (due to restricted access
to the relatively few laboratories with the required safety
levels to conduct tests on COVID 19) both COVID19 and NL63, along
with all coronaviruses, have an enveloped human coronavirus that
has protein spikes on its surface. Theoretical calculations
conducted by the UCL and Cambridge Scientists at CodiKoat have
demonstrated that the electrical charge mechanism of virus
inactivation used in Govirol will also be applicable to SARS-CoV-2
protein spikes resulting in the destruction of the virus.
The CodiKoat technology is nothing
like a vaccine, it is a surface coating that works by crippling the
protein spikes of coronaviruses within seconds of contact. This is
further evidenced by CodiKoat's own tests on the MHV coronavirus
which had exactly the same results as the NL63 test.
By way of analogy: fire burns all
organisms, there is no need to test it on every animal to verify
that fact. In the same way, the CodiKoat technology is fully
expected to disable all coronavirus spike proteins within seconds
of contact. However GreenBank is not making any express or implied
claims that the CodiKoat products described herein have been
specifically tested on the ability to eliminate, cure, or contain
COVID-19 (or SARS-2 Coronavirus) at this time.
Acetate-film treated with
CodiKoat's coating has been proven to kill 90% of human coronavirus
particles within 2 seconds of contact time and is over 99%
effective within just 10 seconds. Testing appears to show that
GoVirol offers similarly powerful protection against virtually all
other harmful microbes, bacteria and fungi.
On the completion of the pilot
tests, CodiKoat Co-founder Dr. Matin Mohseni said, "We're
incredibly proud to have completed our trial at the prestigious
Royal Opera House. The results have been fantastic and it's
incredibly encouraging to see the durability in the performance of
GoVirol. Our exceptional team continues to work towards bringing
this technology to the world and helping to battle viral and
bacterial transmission".
Terry Pullen CEO of GreenBank
commented "We are deeply impressed by the trial results
achieved by CodiKoat. This fully justifies our confidence in the
CodiKoat technology and management team, and we have increasingly
high hopes for the positive health impact that the CodiKoat
technology will have in the healthcare, touch screen device and
hospitality sectors"
Alongside the GoVirol coating,
CodiKoat are continuing to develop other antiviral solutions that
will help protect from harmful bacteria and viruses in years to
come. Testing continues on an antiviral face mask, an air
filtration system that destroys harmful air pollutants and viral
threats, as well as a host of other applications for this
ground-breaking tech.
GreenBank purchased an initial 5%
stake in CodiKoat and has the option to increase this to 15% as
detailed in its announcement of May 4th 2021.
For the purposes of this release,
GreenBank is relying upon the ISO report produced by independent
laboratory Virology Research Services LTD ( see https://virologyresearchservices.com/about/ ) who
conducted the independent ISO tests and who issued the 21702:2019
certification, as well as the highly regarded scientists who
Co-founded CodiKoat. Dr. Reza Saberi Moghaddam, (CodiKoat
co-founder) holds a PhD in physics from the University of Cambridge
and has over 12 years' experience in materials development
processes and holds a portfolio of patents on coating techniques.
Dr. Matin Mohseni (CodiKoat co-founder), is a biomedical scientist
and engineer. He holds a PhD in development and targeting of metal
oxide nanoparticles from University College, London and has several
publications in related scientific journals. Dr. Payam
Nahavandi (CodiKoat Co-founder) is a biomedical engineer who holds
a PhD in Medical Imaging from University College London
About CodiKoat
CodiKoat are a Cambridge-based
biotech company developing ground-breaking antiviral technology.
Born in response to the coronavirus pandemic, CodiKoat have
developed a team of industry-leading scientific and business minds
to help bring their potentially lifesaving technology to the
world.
CodiKoat's technology works by
using surface-functionalized nanostructures to inactivate viruses
within seconds of contact. It also has the same effect on
bacteria and fungi. CodiKoat have developed a high-precision
coating process to apply their product in a highly controllable and
uniform manner. This provides a strong chemistry of nanostructures
with the surface, which leads to high durability, lasting for the
whole product lifetime. CodiKoat technology can coat any
surface — be it hard or soft, rough or smooth, curved or flat —
with nanoparticles of any composition and size. CodiKoat materials
can be easily tuned at an atomic scale and integrated into existing
manufacturing lines for any product.
About GreenBank
GreenBank is a next generation
merchant banking business that has a flexible low-cost overhead
structure designed to maximize profitability. Our management are
based in Toronto, Dallas and London and are used to working across
borders remotely. Our model of remote working, dynamic space and
flexible contracts —rather than large fixed costs – establishes
GreenBank as a global merchant bank for the future, both during and
after COVID19.
GreenBank is listed on the Canadian
Securities Exchange, the Frankfurt Boerse and on the OTC Markets in
the USA. (Trading symbols CSE:
GBC and FRA: 2TL and OTCMKTS:
GRNBF). GreenBank invests in undervalued exponential
growth companies focused on building consistent capital
appreciation for its shareholders.
For details of our "6 Key Drivers
of Value" please see our latest Investor Presentation:
https://greenbankcapitalinc.com/wp-content/uploads/2020/11/03.11.20_Greenbank-Deck-compressed.pdf
For more information please visit
our website www.GreenBankCapitalInc.com or contact Mark
Wettreich at +1 (214) 202-4353 or by email Mark@GreenBankCapitalinc.com
Greenbank Capital (PK) (USOTC:GRNBF)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Greenbank Capital (PK) (USOTC:GRNBF)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
